Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.

Axel Le Cesne,Jean-Yves Blay,Didier Cupissol,Antoine Italiano,Corinne Delcambre,Nicolas Penel,Nicolas Isambert,Christine Chevreau,Emmanuelle Bompas,François Bertucci,L. Chaigneau,Sophie Piperno-Neumann,Sébastien Salas,Maria Rios,C. Guillemet,Jacques-Olivier Bay,Isabelle Ray-Coquard,L. Haddag,Olivier Mir,Stéphanie Foulon

Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.

2018

11508Background: With the exception of a study in translocation-related STS (Kawai, 2015), T has never been compared to BSC in a study including patients (pts) with all sarcoma histotypes. The effi...

Keywords:

Physical therapy
Trabectedin
General surgery
Sarcoma
Soft tissue sarcoma
Medicine
Oncology
in patient
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations